지베이스

지베이스 (chief executive) discloses dealings in 3 companies, chiefly 에이프로젠, 에이프로젠바이오로직스 and 엔투텍. We count 100 filings; the first trade dates from 9 June 2021 and the latest from 8 October 2026.

Market trades split into 12 purchases (€1.2M) and 57 sales (€3.4M). The totals exclude 65 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2026 to date brings 7 purchases and 7 sales.

The 11 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 8 October 2026: a transaction, in 에이프로젠. The last purchase on record was published on 16 July 2026, which is 94 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 3 days. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.